Table 1 Demographics and clinical characteristics
Treatment group | No-treatment group | |
|---|---|---|
Age average (years) | 50 | 44 |
20–40 | 28 (23.9 %) | 8 (40 %) |
41–50 | 30 (25.6 %) | 4 (20 %) |
51–60 | 34 (29.1 %) | 6 (30 %) |
61–80 | 25 (21.4 %) | 2 (10 %) |
Gender—number (%) | ||
Male | 61 (52.1 %) | 8 (40 %) |
Female | 56 (47.9 %) | 12 (60 %) |
Race—number (%) | ||
African American | 31 (26.5 %) | 9 (45 %) |
Caucasian | 66 (56.4 %) | 7 (35 %) |
Hispanic | 11 (9.4 %) | 1 (5 %) |
Other | 9 (7.7 %) | 3 (15 %) |
Years since diagnosis by physician | 0.5–40 (range), 10.7 (mean), 5.0 (median) | 0.5–17 (range), 7.3 (mean), 4.5 (median) |
Years since initial episode | 0.5–48 (range), 13.6 (mean), 9.0 (median) | 0.5–17 (range), 11.4 (mean), 10.3 (median) |
Diagnosed by physician—number (%) | 91 (77.8 %) | 17 (85 %) |
Lab test performed (out of those diagnosed by a physician)—number (%) | 60 (65.9 %) | 9 (52.9 %) |
Symptoms of infection—number (%) | ||
Genital blisters/ulcers | 102 (87.2 %) | 18 (90 %) |
Anal blisters/ulcers | 21 (17.9 %) | 5 (25 %) |
Burning feeling while urinating | 28 (23.9 %) | 4 (20 %) |
Local pain | 83 (70.9 %) | 16 (80 %) |
Genital discharge | 14 (12.0 %) | 1 (5 %) |
General discomfort | 64 (54.7 %) | 11 (55 %) |
Light sensitivity | 22 (18.8 %) | 2 (10 %) |
Genital tingling sensation | 80 (68.4 %) | 13 (65 %) |
Genital itching sensation | 80 (68.4 %) | 13 (65 %) |
Flu-like symptoms | 51 (43.6 %) | 8 (40 %) |
Duration of treatment (months)—number (%) | ||
2–3 | 22 (16.2 %) | N/A |
4–6 | 24 (17.6 %) | N/A |
8–12 | 31 (22.8 %) | N/A |
16–24 | 25 (18.4 %) | N/A |
25–48 | 14 (10.3 %) | N/A |
Dosage of treatment (capsules per day)—number (%) | ||
1 | 40 (31.2 %) | N/A |
2 | 72 (56.3 %) | N/A |
3 | 5 (3.9 %) | N/A |
4 | 11 (8.6 %) | N/A |